{
  "schemaVersion": "orion-company-promise-record-v1",
  "ticker": "SEPN",
  "company": "Septerna",
  "url": "https://www.orionbiotechai.com/company/SEPN",
  "generatedFrom": "founder-checked batch, as of 2026-10-12",
  "records": [
    {
      "chainId": "SEPN-P1",
      "program": "SEP-479 · report Phase 1 data from both the SAD and MAD cohorts",
      "eventLabel": "Clinical results disclosure",
      "status": "Timing changed",
      "statusDefinition": "https://www.orionbiotechai.com/orion-methodology.html#promise-status-timing-changed",
      "firstStated": {
        "statement": "Anticipate topline data in late 2026 / early 2027",
        "window": "in late 2026 / early 2027",
        "documentType": "SEC Exhibit 99.1",
        "date": "2026-01-12",
        "dateBasis": "filing_date",
        "url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526009864/d81130dex991.htm"
      },
      "restatements": [
        {
          "kind": "Statement retained",
          "statement": "Septerna anticipates reporting data from the trial in late 2026 or early 2027.",
          "window": "in late 2026 or early 2027",
          "documentType": "SEC Exhibit 99.1",
          "date": "2026-04-13",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/d57504dex991.htm"
        },
        {
          "kind": "Statement retained",
          "statement": "We anticipate reporting data from the trial in late 2026 or early 2027.",
          "window": "late 2026 or early 2027",
          "documentType": "SEC Form 10-Q",
          "date": "2026-05-11",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526216759/sepn-20260331.htm"
        },
        {
          "kind": "Wording changed",
          "statement": "As a result, Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.",
          "window": "in the first quarter of 2027",
          "documentType": "Company press release",
          "date": "2026-08-10",
          "dateBasis": "company_release",
          "url": "https://ir.septerna.com/news-releases/news-release-details/septerna-highlights-business-progress-and-reports-second-0"
        },
        {
          "kind": "Wording changed",
          "statement": "As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.",
          "window": "in the first quarter of 2027",
          "documentType": "SEC Form 10-Q",
          "date": "2026-08-10",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm"
        }
      ],
      "disclosure": null,
      "wordingChanges": [
        {
          "date": "2026-08-10",
          "fromSources": [
            {
              "statement": "We anticipate reporting data from the trial in late 2026 or early 2027.",
              "window": "late 2026 or early 2027",
              "documentType": "SEC Form 10-Q",
              "date": "2026-05-11",
              "dateBasis": "filing_date",
              "url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526216759/sepn-20260331.htm"
            }
          ],
          "toSources": [
            {
              "statement": "As a result, Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.",
              "window": "in the first quarter of 2027",
              "documentType": "Company press release",
              "date": "2026-08-10",
              "dateBasis": "company_release",
              "url": "https://ir.septerna.com/news-releases/news-release-details/septerna-highlights-business-progress-and-reports-second-0"
            },
            {
              "statement": "As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.",
              "window": "in the first quarter of 2027",
              "documentType": "SEC Form 10-Q",
              "date": "2026-08-10",
              "dateBasis": "filing_date",
              "url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm"
            }
          ]
        }
      ],
      "additionalDisclosures": [],
      "scopeNotes": [
        "The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.",
        "Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial."
      ],
      "scopeSources": [],
      "contextDisclosures": [
        {
          "kind": "Context disclosed",
          "documentType": "SEC Form 10-Q",
          "date": "2026-08-10",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm",
          "eventDate": null,
          "eventLabel": null,
          "sourceLocator": "Part I, Item 2: Recent Developments, SEP-479 PTH1R Agonist Program; paragraph beginning Based on pharmacokinetic data (page 23)",
          "excerpts": [
            "To fully characterize steady-state pharmacokinetics, dosing for the MAD cohorts will be extended to 14 days."
          ]
        }
      ],
      "companyReleases": [
        {
          "date": "2026-08-10",
          "url": "https://ir.septerna.com/news-releases/news-release-details/septerna-highlights-business-progress-and-reports-second-0"
        },
        {
          "date": "2026-09-10",
          "url": "https://ir.septerna.com/news-releases/news-release-details/septerna-inc-announces-inducement-grant-under-nasdaq-listing"
        }
      ],
      "companySourceChecks": [
        {
          "url": "https://ir.septerna.com/press-releases",
          "checkedDate": "2026-10-10",
          "label": "Company press release listing"
        }
      ],
      "secCheckedThrough": "2026-08-10",
      "secScope": "8-K and Ex-99.1 Jan–Aug 2026, 10-Q Mar 31 and Jun 30 checked; Aug 10 states Q1 2027 with reason.",
      "companyPrCheckedDate": "2026-10-10",
      "companyPrScope": "Press releases page checked on Oct 10, latest items reviewed.",
      "founderCheckedDate": "2026-10-10",
      "rowsShown": 1,
      "rowsTotal": 1,
      "citation": "Septerna (SEPN) — SEP-479 · report Phase 1 data from both the SAD and MAD cohorts: “in late 2026 / early 2027” (SEC Exhibit 99.1 2026-01-12); statement retained “in late 2026 or early 2027” (2026-04-13); statement retained “late 2026 or early 2027” (2026-05-11); wording changed from “late 2026 or early 2027” (2026-05-11) to “in the first quarter of 2027” (2026-08-10); wording changed from “late 2026 or early 2027” (2026-05-11) to “in the first quarter of 2027” (2026-08-10). Status Timing changed, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1984086/000119312526009864/d81130dex991.htm | https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/d57504dex991.htm | https://www.sec.gov/Archives/edgar/data/1984086/000119312526216759/sepn-20260331.htm | https://ir.septerna.com/news-releases/news-release-details/septerna-highlights-business-progress-and-reports-second-0 | https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm",
      "corrections": [
        {
          "date": "2026-10-10",
          "what": "Corrected the April 13 event label to Statement retained; removed that equivalent expression from Wording changes.",
          "why": "The comparison treats late 2026 / early 2027 and late 2026 or early 2027 as equivalent timing alternatives. Original quotations are retained.",
          "evidence": "January 12 SEC Exhibit 99.1 and April 13 SEC Exhibit 99.1, retained in First stated and Changes."
        },
        {
          "date": "2026-10-10",
          "what": "Added the August 10 10-Q sentence about extending MAD cohort dosing to 14 days as a Context disclosed row.",
          "why": "Founder requested the exact company quotation and original filing link.",
          "evidence": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm"
        },
        {
          "date": "2026-10-10",
          "what": "Updated the Changes explanation to: Status is set by founder review of the original filings.",
          "why": "The status is the founder-selected status retained in the reviewed record.",
          "evidence": "Founder correction request on 2026-10-10; the reviewed Timing changed status is retained."
        }
      ]
    }
  ]
}